Literature DB >> 18555375

Continuous hybridoma growth and monoclonal antibody production in hollow fiber reactors-separators.

G L Altshuler1, D M Dziewulski, J A Sowek, G Belfort.   

Abstract

Growth of a hybridoma culture, along with production of monoclonal antibody, was demonstrated over extended periods in polysulfone hollow fiber membrane modules. The molecular weight cutoffs of the membranes were 70,000, 50,000, and 100,000 daltons. The hybridoma cell line, designated 65/26, produced IgG (2b/kappa) directed at mouse thymus cell surface antigen, TL.1. Cell growth occurred in the shell space of the reactor, using supplemented RPMI 1640 (20% fetal bovine serum) supplied from a separate reservoir vessel through the hollow fiber lumen. The reservoir contained 125 mL media, which was changed every 4 days. Concentrations of immunoglobulin were determined by an enzyme immunoassay (using protein A and alkaline phosphatase-labeled antibody conjugate). For the 10K, 50K, and 100K hollow fiber membrane modules, the maximum IgG concentrations detected in the 2.5-mL shell space were 47.5-80, 510, and 740 mug/mL, respectively. In the 125-mL reservoir for the 100K hollow fiber membrane module, the IgG concentration was measured at 260 mug/mL These values compare with an IgG concentration of 1 mug/mL when grown in a standard tissue culture flask and 3.2-7.6 mug/mL when grown in 100 ml media in a spinner flask. In addition, 10K and 50K hollow fiber membrane modules were run in a mode that decreased the fetal bovine serum supplement with time. Differences between these systems suggest that it is possible to obtain high IgG accumulation rates, both during and after the exponential growth phase of the hybridoma population.

Entities:  

Year:  1986        PMID: 18555375     DOI: 10.1002/bit.260280503

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  15 in total

Review 1.  Serum-free medium for fermentor cultures of hybridomas.

Authors:  O W Merten; J Litwin
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

2.  A comparison of different culture methods for hybridoma propagation and monoclonal antibody production.

Authors:  C P Marquis; C Harbour; J P Barford; K S Low
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.058

3.  Batch production and growth kinetics of hybridomas.

Authors:  O W Merten
Journal:  Cytotechnology       Date:  1988-02       Impact factor: 2.058

4.  High cell density perfusion cultures of anchorage-dependent Vero cells in a depth filter perfusion system.

Authors:  S K Choi; H N Chang; G M Lee; I H Kim; D J Oh
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

5.  Long-term Continuous Production of Monoclonal Antibody by Hybridoma Cells Immobilized in a Fibrous-Bed Bioreactor.

Authors:  Hui Zhu; Shang-Tian Yang
Journal:  Cytotechnology       Date:  2004-01       Impact factor: 2.058

6.  Mass transfer effects in microencapsulated hybridoma cells producing monoclonal antibodies.

Authors:  W W Edmunds; F Kargi; C Sorenson
Journal:  Appl Biochem Biotechnol       Date:  1989 Jan-Aug       Impact factor: 2.926

7.  Performance of a membrane-dialysis bioreactor with a radial-flow fixed bed for the cultivation of a hybridoma cell line.

Authors:  A Bohmann; R Pörtner; H Märkl
Journal:  Appl Microbiol Biotechnol       Date:  1995-10       Impact factor: 4.813

8.  The influence of dissolved oxygen tension on the metabolic activity of an immobilized hybridoma population.

Authors:  J Thömmes; J Gätgens; M Biselli; P W Runstadler; C Wandrey
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Calcium alginate immobilized hybridomas grown using a fluidized-bed perfusion system with a protein-free medium.

Authors:  B Shen; P Greenfield; S Reid
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

10.  Transferrin recycling perfusion culture of hybridoma cells.

Authors:  Y Takazawa; M Tokashiki
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.